| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
AMD macular degenerationPegaptanibRanibizumabVEGFBevacizumabSunitinibSorafenib| 1 | 2006 | Pegaptanib in the treatment of wet, age-related macular degeneration. | 
| + | - | nl | Int J Nanomedicine 1(3):263-8 (2006) Vinores SA |
| 2 | 2008 | Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. |
| + | - | nl | Health Technol Assess 12(16):iii-iv, ix-201 (2008) Colquitt JL |
| 3 | 2007 | A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin). |
| + | - | nl | Indian J Ophthalmol 55(6):437-9 (2007) |
| 4 | 2007 | Pegaptanib sodium for ocular vascular disease. |
| + | - | nl | Indian J Ophthalmol 55(6):427-30 (2007) |
| 5 | 2007 | Vascular endothelial growth factor: biology and therapeutic applications. |
| + | - | nl | Int J Biochem Cell Biol 39(7-8):1349-57 (2007) |
